Portal Hypertension & Cirrhosis was confirmed in the ESCI database and is expected to receive its first impact factor in 2025.

The Chinese Medical Journal earns a higher impact factor of 7.5, ranking the top of journals (Q1, 6.15%).

Intelligent Medicine harvests the first impact factor of 4.4. Ranked in Q1 region in COMPUTER SCIENCE.

Cancer Pathogenesis and Therapy has been selected for inclusion in PubMed/PubMed Central (PMC) on Jan 30, 2024.

the Journal of Pancreatology was officially confirmed to be included in the ESCI database and is expected to receive its first impact factor in 2024.

Intelligent Medicine has been officially confirmed to be included in ESCI and will receive its first impact factor in 2024.

Portal Hypertension & Cirrhosis has been evaluation by the Content Selection & Advisory Board (CSAB) and advised to accept in Scopus.

Partnership Provides Chinese Rightsholder with Access to New Markets While Offering Researchers Key Medical Science and Technology Content

China fully vaccinated 82.5% of people, close to herd immunity.

Chinese Vice Premier Sun Chunlan on Dec 13 stressed China's efforts to deepen international health cooperation and make a greater contribution to promoting global health equity.

A total of 74 new medications have been added to China's national medical insurance catalog, with prices of 67 medicine types slashed by an average of 61.71 percent.

Guide to wearing masks amid COVID-19 for general public.

About 2.355b COVID-19 vaccine doses administered on Chinese mainland

Beijing tightens measures as new infection cluster reported.

China's National Health Commission has rolled out a work plan to improve the comprehensive capabilities of county-level hospitals.